Lanzarini L, Fetiveau R, Previtali M, Poli A, Barberis P D, Mussini A, Montemartini C
Divisione di Cardiologia, IRCCS-Policlinico S. Matteo, Pavia.
G Ital Cardiol. 1994 Sep;24(9):1093-101.
The clinical experience with dipyridamole stress echocardiography for the diagnosis of coronary artery disease (CAD) revealed that patients with less severe extent of CAD and limited impairment of coronary reserve are frequently not recognized by the test. Increasing myocardial oxygen consumption adding atropine to dipyridamole may improve the diagnostic accuracy of dipyridamole for the detection of CAD.
Fifty-two patients (48 men, aged 53 +/- 7 years) underwent a high-dose dipyridamole-echo stress test (0.84 mg/kg over 10 minutes) and coronary arteriography within 15 days from the test. Eighteen out of 52 patients were referred for chest pain; 11 suffered from a previous myocardial infarction (MI) and 23 were studied in the early phase after a first acute MI. Starting after 4 minutes from the end of dipyridamole infusion, atropine was added, in 2 doses of 0.5 mg each, at 1-minute interval in those patients with no echocardiographic evidence of myocardial ischemia after dipyridamole alone. Left ventricular wall motion was analyzed on a 11-segment left ventricular model in a qualitative manner.
Dipyridamole-echo stress test was positive in 23/52 (44%) and negative in 29/52 (56%) patients. In these patients atropine was added resulting in an additional echo positivity in 14/29 patients. Coronary arteriography was normal in 6 patients (12%); 1-vessel CAD was diagnosed in 23 (44%), 2-vessel CAD in 13 (25%) and 3-vessel CAD in 10 (19%) cases. The sensitivity for CAD diagnosis was 48% (22/46) for dipyridamole alone and 76% (35/46) for dipyridamole-atropine echo (p < .005), while the specificity was 83% (5/6) and 80% (4/5) respectively. Diagnostic accuracy increased from 52% (27/52) to 75% (39/52) (p < .001). The better diagnostic accuracy of dipyridamole-atropine echo stress test was mainly related to the increased sensitivity of the combined test in patients with 1-vessel CAD (from 39% to 70%) (p < .005). Peak heart rate was significantly higher after the addition of atropine (100 +/- 17 beats/min) compared to basal (64 +/- 10) and dipyridamole (85 +/- 12) in those patients with a positive dipyridamole-atropine echo stress test. No limiting side effects were elicited with the addition of atropine to dipyridamole.
The combination of atropine and dipyridamole induces a chronotropic stress adjunctive to flow maldistribution phenomena that permits to increase diagnostic accuracy of dipyridamole-echo stress test particularly in patients with less severe extent of CAD; it is usually well tolerated and safe and may be considered as a useful procedure for optimizing diagnostic value of dipyridamole-echo stress test.
双嘧达莫负荷超声心动图诊断冠状动脉疾病(CAD)的临床经验显示,CAD程度较轻且冠状动脉储备功能受损有限的患者常无法通过该检查被识别。在双嘧达莫基础上加用阿托品增加心肌氧耗量,可能会提高双嘧达莫检测CAD的诊断准确性。
52例患者(48例男性,年龄53±7岁)在试验后15天内接受了高剂量双嘧达莫-超声负荷试验(10分钟内静脉注射0.84mg/kg)及冠状动脉造影。52例患者中18例因胸痛就诊;11例有既往心肌梗死(MI)病史,23例在首次急性MI后的早期阶段接受研究。在双嘧达莫输注结束4分钟后,对于单独使用双嘧达莫后超声心动图未显示心肌缺血证据的患者,每隔1分钟分2次给予0.5mg阿托品。采用11节段左心室模型定性分析左心室壁运动。
双嘧达莫-超声负荷试验结果为阳性的患者有23/52例(44%),阴性的有29/52例(56%)。对这些患者加用阿托品后,29例中有14例超声心动图转为阳性。冠状动脉造影正常的有6例(12%);诊断为单支血管CAD的有23例(44%),双支血管CAD的有13例(25%),三支血管CAD的有10例(19%)。单独使用双嘧达莫诊断CAD的敏感性为48%(22/46),双嘧达莫-阿托品超声心动图的敏感性为76%(35/46)(p<0.005),特异性分别为83%(5/6)和80%(4/5)。诊断准确性从52%(27/52)提高到75%(39/52)(p<0.001)。双嘧达莫-阿托品超声负荷试验诊断准确性的提高主要与联合试验对单支血管CAD患者敏感性的增加有关(从39%提高到70%)(p<0.005)。双嘧达莫-阿托品超声负荷试验结果为阳性的患者,加用阿托品后的心率峰值(每分钟100±17次)显著高于基础心率(每分钟64±10次)和双嘧达莫用药时的心率(每分钟85±12次)。双嘧达莫加用阿托品未引发明显的副作用。
阿托品与双嘧达莫联合应用可诱发变时性负荷,辅助血流分布异常现象,从而提高双嘧达莫-超声负荷试验的诊断准确性,尤其是对于CAD程度较轻的患者;该方法通常耐受性良好且安全,可被视为优化双嘧达莫-超声负荷试验诊断价值的有效手段。